Does the media favor SXTP or CABR?

In the previous week, Caring Brands had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Caring Brands and 1 mentions for 60 Degrees Pharmaceuticals. Caring Brands' average media sentiment score of 0.83 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that Caring Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caring Brands 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FNCH or SXTP?

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,389.09%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor SXTP or MBRX?

In the previous week, Moleculin Biotech had 7 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 8 mentions for Moleculin Biotech and 1 mentions for 60 Degrees Pharmaceuticals. Moleculin Biotech's average media sentiment score of 0.11 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moleculin Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SXTP or ASBP?

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, suggesting a potential upside of 1,389.09%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SXTP or ASBP more profitable?

60 Degrees Pharmaceuticals has a net margin of -650.21% compared to Aspire Biopharma's net margin of -11,362.21%. Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals -650.21% N/A -136.81% Aspire Biopharma -11,362.21% N/A -177.59%

60 Degrees Pharmaceuticals (SXTP) Competitors

$0.93 -0.02 (-2.04%)

Closing price 09/3/2026 03:57 PM Eastern

Extended Trading

$0.97 +0.04 (+4.72%)

As of 04:01 AM Eastern

Compare

SXTP vs. INTS, CABR, FNCH, MBRX, and ASBP

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? 60 Degrees Pharmaceuticals's main competitors and comparable companies include Intensity Therapeutics (INTS), Caring Brands (CABR), Finch Therapeutics Group (FNCH), Moleculin Biotech (MBRX), and Aspire Biopharma (ASBP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 60 Degrees Pharmaceuticals compare to Intensity Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

60 Degrees Pharmaceuticals has higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
60 Degrees Pharmaceuticals	$1.41M	2.32	-$7.36M	-$4.82	N/A

Intensity Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

Intensity Therapeutics has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
60 Degrees Pharmaceuticals	Neutral

Intensity Therapeutics presently has a consensus price target of $7.00, indicating a potential upside of 75.00%. 60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,389.09%. Given 60 Degrees Pharmaceuticals' higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Intensity Therapeutics beats 60 Degrees Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Caring Brands?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Caring Brands (NASDAQ:CABR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Caring Brands has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Caring Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
Caring Brands	N/A	-1,153.12%	-322.63%

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 14.6% of Caring Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Caring Brands had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Caring Brands and 1 mentions for 60 Degrees Pharmaceuticals. Caring Brands' average media sentiment score of 0.83 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that Caring Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caring Brands	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 1,389.09%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Caring Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Caring Brands has lower revenue, but higher earnings than 60 Degrees Pharmaceuticals. Caring Brands is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.32	-$7.36M	-$4.82	N/A
Caring Brands	N/A	N/A	-$6.28M	-$0.74	N/A

Summary

60 Degrees Pharmaceuticals beats Caring Brands on 8 of the 14 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 equaled 60 Degrees Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
60 Degrees Pharmaceuticals	Neutral

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,389.09%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
60 Degrees Pharmaceuticals	$1.41M	2.32	-$7.36M	-$4.82	N/A

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Finch Therapeutics Group has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

Summary

60 Degrees Pharmaceuticals beats Finch Therapeutics Group on 10 of the 14 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Moleculin Biotech?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 1,389.09%. Moleculin Biotech has a consensus target price of $3.00, indicating a potential upside of 344.12%. Given 60 Degrees Pharmaceuticals' higher probable upside, equities research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than Moleculin Biotech. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.32	-$7.36M	-$4.82	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Moleculin Biotech had 7 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 8 mentions for Moleculin Biotech and 1 mentions for 60 Degrees Pharmaceuticals. Moleculin Biotech's average media sentiment score of 0.11 beat 60 Degrees Pharmaceuticals' score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moleculin Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moleculin Biotech has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
Moleculin Biotech	N/A	-143.51%	-24.53%

Summary

Moleculin Biotech beats 60 Degrees Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Aspire Biopharma?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

60 Degrees Pharmaceuticals has higher revenue and earnings than Aspire Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.32	-$7.36M	-$4.82	N/A
Aspire Biopharma	$10K	1,295.00	-$24.48M	-$69.62	N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Aspire Biopharma. 60 Degrees Pharmaceuticals' average media sentiment score of 0.00 equaled Aspire Biopharma'saverage media sentiment score.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Neutral
Aspire Biopharma	Neutral

60 Degrees Pharmaceuticals has a net margin of -650.21% compared to Aspire Biopharma's net margin of -11,362.21%.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%
Aspire Biopharma	-11,362.21%	N/A	-177.59%

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, suggesting a potential upside of 1,389.09%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Summary

60 Degrees Pharmaceuticals beats Aspire Biopharma on 10 of the 14 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTP vs. The Competition

Export

Metric	60 Degrees Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.34M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.19	787.27	273.29	25.25
Price / Sales	2.32	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-0.47	12.33	12.92	6.14
Net Income	-$7.36M	$2.82B	$3.47B	$349.01M
7 Day Performance	-9.70%	2.60%	0.60%	-0.27%
1 Month Performance	-24.38%	6.96%	5.72%	0.68%
1 Year Performance	-84.29%	9.45%	25.33%	14.84%

60 Degrees Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTP 60 Degrees Pharmaceuticals	1.8979 of 5 stars	$0.93 -2.0%	$13.85 +1,389.1%	-84.1%	$3.34M	$1.41M	N/A	3	News Coverage Gap Up
INTS Intensity Therapeutics	2.2671 of 5 stars	$4.53 -7.4%	$7.00 +54.5%	-40.5%	$14.77M	N/A	N/A	2,021	Gap Up High Trading Volume
CABR Caring Brands	0.4441 of 5 stars	$1.33 +3.5%	N/A	N/A	$13.79M	N/A	N/A	4	Gap Down
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
MBRX Moleculin Biotech	3.1703 of 5 stars	$0.60 -1.8%	$22.00 +3,566.7%	-92.8%	$11.69M	N/A	N/A	20	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. INTS, CABR, FNCH, MBRX, and ASBP

How does 60 Degrees Pharmaceuticals compare to Intensity Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to Caring Brands?

Summary

How does 60 Degrees Pharmaceuticals compare to Finch Therapeutics Group?

Summary

How does 60 Degrees Pharmaceuticals compare to Moleculin Biotech?

Summary

How does 60 Degrees Pharmaceuticals compare to Aspire Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. INTS, CABR, FNCH, MBRX, and ASBP

How does 60 Degrees Pharmaceuticals compare to Intensity Therapeutics?

Which has better valuation and earnings, INTS or SXTP?

Is INTS or SXTP more profitable?

Which has more risk and volatility, INTS or SXTP?

Does the media refer more to INTS or SXTP?

Do analysts prefer INTS or SXTP?

Do insiders & institutionals believe in INTS or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to Caring Brands?

Is SXTP or CABR more profitable?

Do institutionals & insiders believe in SXTP or CABR?

Does the media favor SXTP or CABR?

Do analysts recommend SXTP or CABR?

Which has stronger earnings & valuation, SXTP or CABR?

Summary

How does 60 Degrees Pharmaceuticals compare to Finch Therapeutics Group?

Does the media refer more to FNCH or SXTP?

Do analysts recommend FNCH or SXTP?

Which has stronger valuation and earnings, FNCH or SXTP?

Which has more volatility & risk, FNCH or SXTP?

Do insiders and institutionals have more ownership in FNCH or SXTP?

Is FNCH or SXTP more profitable?

Summary

How does 60 Degrees Pharmaceuticals compare to Moleculin Biotech?

Do analysts recommend SXTP or MBRX?

Which has more volatility and risk, SXTP or MBRX?

Which has preferable valuation and earnings, SXTP or MBRX?

Do insiders & institutionals believe in SXTP or MBRX?

Does the media favor SXTP or MBRX?

Is SXTP or MBRX more profitable?

Summary

How does 60 Degrees Pharmaceuticals compare to Aspire Biopharma?

Which has higher valuation and earnings, SXTP or ASBP?

Does the media favor SXTP or ASBP?

Is SXTP or ASBP more profitable?

Do analysts rate SXTP or ASBP?

Do insiders and institutionals have more ownership in SXTP or ASBP?

Which has more risk and volatility, SXTP or ASBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools